First Trial of CRISPR-Edited T cells in Lung Cancer.

  title={First Trial of CRISPR-Edited T cells in Lung Cancer.},
  author={Simon F. Lacey and Joseph A. Fraietta},
  journal={Trends in molecular medicine},
Targeting Cancer with CRISPR/Cas9-Based Therapy
Recent advancements in cancer-selective treatments based on the CRISPR/Cas9 system are described, especially focusing on strategies for targeted delivery of the CRisPR/cas9 machinery to affected cells, controlling Cas9 expression in tissues of interest and disrupting cancer-specific genes to result in selective death of malignant cells.
The Potential of CRISPR-Guided Therapies in the Dermatology Clinic
Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy
The recent progress in exploring the regulatory mechanism of tumor immune PD-1 and programmed death ligand 1(PD-L1) based on CRISPR/Cas9 technology and its clinical application in different cancer types are summarized.
Epigenetic Alterations and Inflammation as Emerging Use for the Advancement of Treatment in Non-Small Cell Lung Cancer
Investigation on such topic is most likely to shed light on the molecular and immunological mechanisms of epigenetic and inflammatory factors and promote the application of epigenetics in the innovative diagnostic and therapeutic strategies for NSCLC.


Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer
In a first-in-human phase I trial of patients with advanced lung cancer, infusions of autologous T cells edited to delete the PD-1 gene via CRISPR–Cas9 were well tolerated and did not lead to severe treatment-related adverse events.
CRISPR-engineered T cells in patients with refractory cancer
This first-in-human, phase 1 clinical trial was designed to test the safety and feasibility of multiplex CRISPR-Cas9 gene editing of T cells from patients with advanced, refractory cancer and found the persistence of the T cells expressing the engineered TCR was much more durable than in three previous clinical trials during which T cells were infused.
CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia.
Although this study transplanted CRISPR-edited CCR5-ablated hematopoietic stem and progenitor cells (HSPCs) into a patient with HIV-1 infection and acute lymphoblastic leukemia, the percentage of C CR5 disruption in lymphocytes was only approximately 5%, which indicates the need for further research into this approach.
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
By using gene editing to simultaneously introduce the CAR and disrupt TCR and CD52 in T cells, the authors generated functional CAR T cells that could evade host immunity for use in unmatched recipients and demonstrates the therapeutic potential of gene-editing technology.
iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity
An improvement of the GUIDE-seq method, iGUIDE, is reported, which allows filtering of mispriming events to clarify the true cleavage signal and specifies the locations of Cas9-guided cleavage for four guide RNAs.